Hologic (HOLX) Outpaces Stock Market Gains: What You Should Know – Yahoo Finance

Hologic (HOLX) closed the most recent trading day at $74.80, moving +1.36% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.75%. Elsewhere, the Dow gained 0.55%, while the tech-heavy Nasdaq lost 0.01%.
Coming into today, shares of the medical device maker had gained 2.34% in the past month. In that same time, the Medical sector gained 5.42%, while the S&P 500 gained 3.49%.
Investors will be hoping for strength from Hologic as it approaches its next earnings release. In that report, analysts expect Hologic to post earnings of $0.87 per share. This would mark a year-over-year decline of 59.91%. Meanwhile, our latest consensus estimate is calling for revenue of $962.24 million, down 34.59% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.46 per share and revenue of $3.81 billion. These totals would mark changes of -42.52% and -21.56%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Hologic. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Hologic currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Hologic is currently trading at a Forward P/E ratio of 21.3. This valuation marks a discount compared to its industry's average Forward P/E of 28.3.
It is also worth noting that HOLX currently has a PEG ratio of 1.4. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical – Instruments stocks are, on average, holding a PEG ratio of 2.33 based on yesterday's closing prices.
The Medical – Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 92, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Hologic, Inc. (HOLX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Related Quotes
In the latest trading session, Alcoa (AA) closed at $47.28, marking a +1.46% move from the previous day.
Despite the volatility and slowing growth, long-term investors might consider buying stocks in December for 2023, even if that means starting tiny positions or dollar-cost averaging into blue chips. The two stocks we explore today are Intuit and Mastercard…
Is it time to bet on a turnaround?
Wake up and smell the diesel.
Yahoo Finance Live's Seana Smith breaks down the stocks trending in the after-hours trading session.
Investors searching for that feeling telling you market sentiment is shifting to a more positive outlook have been brought down to earth again. Following 2022’s market behavior to a tee, the recent rally has run into a brick wall. To wit, the S&P 500 notched 5 consecutive negative sessions over the last week with investors mulling over the prospect of a recession. Indeed, financial experts have been sounding the warning bells on the precarious state of the global economy. One of the doomsayers h
At age 51, Anne Schieber was broke and disillusioned. She had worked for the IRS for 23 years and was regarded as one of the agency’s top auditors. But she never got promoted and never earned more than $3,150 in a year. With half her life already behind her, her retirement prospects looked bleak. But Schieber had learned a powerful secret from years of studying the tax returns of America’s richest residents. Over the next 50 years, it earned her a 449,000% return — making Schieber one of the mos
Buy and hold forever? Not always.
Sam Bankman-Fried's ambition for celebrity endorsements might have snared the "Anti-Hero" singer, but she proved to be smarter than a lot of other famous people.
After falling for much of the week, the major stock market indexes were gaining ground early Thursday as investors digested the latest unemployment numbers. Last week's initial jobless claims suggest the Federal Reserve's campaign to combat inflation may finally be bearing fruit. Investors used that positive development as an excuse to buy up their favorite beaten-down tech stocks.
Earlier this year, in May, claims were made that Microsoft Corp co-founder Bill Gates owned the majority of America’s farmland. While that is false, with the billionaire amassing nearly 270,000 acres of farmland across the country, compared to 900 million total farm acres, a different billionaire privately owns 2.2 million acres, making him the largest landowner in the U.S. John Malone, the former CEO of Tele-Communications Inc., which AT&T Inc. purchased for more than $50 billion in 1999, has a
(Bloomberg) — While Elon Musk is busy overhauling newly acquired Twitter Inc., Tesla Inc. is facing increasingly urgent issues and testing the faith of some of its chief executive’s biggest fans.Most Read from BloombergPutin Calls Russian Nukes Deterrent Factor, Says War Risk RisingTesla's Troubles Are Piling Up While Elon Musk Is Distracted With TwitterWNBA Star Griner Freed in One-for-One Swap for Arms DealerElon Musk’s Bankers Consider Tesla Margin Loans to Cut Risky Twitter DebtPeru’s Presi
In this article, we will discuss the 15 best electric car stocks to buy now. If you want to explore similar stocks, you can also take a look at 5 Best Electric Car Stocks To Buy Now. The Electric Car Industry: An Analysis Electric car stocks are increasingly becoming a popular investment option as the […]
Shares of Summit Therapeutics (NASDAQ: SMMT) were skyrocketing 371.8% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence. This huge gain came after the company announced on Tuesday that it's licensing bispecific antibody ivonescimab from Chinese drugmaker Akeso. Akeso will retain the rights to market the therapy throughout the rest of the world, including China.
The rollercoaster ride continues in the stock market, and equities have been falling across the board this week. The S&P 500 is down 3.5%, and the Dow has lost some 870 points. The market drop was fueled by uncertainty; recent economic data has been unexpectedly positive, and it’s clouded the forecast for the Fed’s interest rate decision next week. The central bank’s twin mandates, to rein in inflation and to moderate unemployment, frequently run counter to each other, and with inflation running
(Bloomberg) — US equity futures rose Friday before a report on US producer prices that will be one of the final pieces of data to inform a rate decision by the Federal Reserve next week. The dollar fell.Most Read from BloombergPutin Calls Russian Nukes Deterrent Factor, Says War Risk RisingTesla's Troubles Are Piling Up While Elon Musk Is Distracted With TwitterWNBA Star Griner Freed in One-for-One Swap for Arms DealerElon Musk’s Bankers Consider Tesla Margin Loans to Cut Risky Twitter DebtPeru
Broadcom Inc. (AVGO) delivered earnings and revenue surprises of 1.75% and 0.38%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
Not many S&P 500 stocks have enough oomph to jump 500% in five years. But a handful show it's more than possible.
L1 Capital International, an investment management company, released its “L1 Capital International Fund” third-quarter 2022 investor letter. A copy of the same can be downloaded here. The fund returned -0.4% net of fees in the third quarter compared to a 0.3% return for the MSCI World Net Total Return Index in AUD. The depreciation of Australian […]
Tesla (TSLA) closed at $173.44 in the latest trading session, marking a -0.34% move from the prior day.

source